Lemaitre Vascular Inc LMAT
We take great care to ensure that the data presented and summarized in this overview for LEMAITRE VASCULAR INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LMAT
View all-
Black Rock Inc. New York, NY3.48MShares$318 Million0.01% of portfolio
-
Conestoga Capital Advisors, LLC1.98MShares$181 Million2.55% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$144 Million0.0% of portfolio
-
Copeland Capital Management, LLC1.16MShares$106 Million1.93% of portfolio
-
Geneva Capital Management LLC878KShares$80.2 Million1.39% of portfolio
-
State Street Corp Boston, MA822KShares$75.1 Million0.0% of portfolio
-
Congress Asset Management CO709KShares$64.8 Million0.46% of portfolio
-
Ranger Investment Management, L.P. Dallas, TX685KShares$62.6 Million4.19% of portfolio
-
Dimensional Fund Advisors LP Austin, TX576KShares$52.6 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA543KShares$49.6 Million0.0% of portfolio
Latest Institutional Activity in LMAT
Top Purchases
Top Sells
About LMAT
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Insider Transactions at LMAT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 12
2024
|
Joseph P Pellegrino Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
596
-3.08%
|
$59,600
$100.28 P/Share
|
Dec 12
2024
|
Joseph P Pellegrino Jr Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22
+0.11%
|
-
|
Dec 12
2024
|
David B Roberts President and Director |
SELL
Payment of exercise price or tax liability
|
Direct |
394
-1.32%
|
$39,400
$100.28 P/Share
|
Dec 12
2024
|
David B Roberts President and Director |
BUY
Exercise of conversion of derivative security
|
Direct |
22
+0.07%
|
-
|
Dec 12
2024
|
Lawrence J Jasinski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6
+0.05%
|
-
|
Dec 12
2024
|
Martha Shadan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6
+0.17%
|
-
|
Dec 12
2024
|
George W Le Maitre Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,316
-0.03%
|
$131,600
$100.28 P/Share
|
Dec 12
2024
|
George W Le Maitre Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
52
+0.0%
|
-
|
Dec 12
2024
|
John A Roush Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6
+0.11%
|
-
|
Dec 12
2024
|
Bridget A Ross Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6
+0.11%
|
-
|
Dec 12
2024
|
John James O'Connor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6
+0.01%
|
-
|
Dec 12
2024
|
Trent G Kamke Senior V. P., Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
178
-1.69%
|
$17,800
$100.28 P/Share
|
Dec 12
2024
|
Trent G Kamke Senior V. P., Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
10
+0.09%
|
-
|
Dec 11
2024
|
Joseph P Pellegrino Jr Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
294
-2.91%
|
$29,694
$101.0 P/Share
|
Dec 11
2024
|
Joseph P Pellegrino Jr Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18
+0.18%
|
-
|
Dec 11
2024
|
David B Roberts President and Director |
SELL
Payment of exercise price or tax liability
|
Direct |
196
-1.29%
|
$19,796
$101.0 P/Share
|
Dec 11
2024
|
David B Roberts President and Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18
+0.12%
|
-
|
Dec 11
2024
|
Lawrence J Jasinski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6
+0.11%
|
-
|
Dec 11
2024
|
George W Le Maitre Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
647
-0.03%
|
$65,347
$101.0 P/Share
|
Dec 11
2024
|
George W Le Maitre Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40
+0.0%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 26.3K shares |
---|---|
Exercise of conversion of derivative security | 93.6K shares |
Open market or private sale | 472K shares |
---|---|
Payment of exercise price or tax liability | 6.36K shares |
Exercise of conversion of derivative security | 6 shares |
Bona fide gift | 26.7K shares |